We are a clinical-stage oncology company dedicated to unlocking a new paradigm
in cancer therapeutics that addresses the significant unmet need in patients,with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root,cause of oncogene amplification observed in more than 14% of cancer patients,Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.
